Skip to main content
TipRanks
Go Ultimate75% OFF

Cerus (CERS) AI Stock Analysis

776 Followers
CERS

Cerus

(NASDAQ:CERS)

Select Model
Rating:56Neutral
Price Target:$2.00â–²(0.76% Upside)
Action:reiterated
Date:11/04/26

The score is driven primarily by improving financial fundamentals (strong multi-year revenue growth, narrowing losses, and sharply reduced leverage), supported by a notably positive earnings call with reaffirmed 2026 guidance and strong clinical/regulatory progress (REDeS top-line results) plus sustained positive adjusted EBITDA. Offsetting this, technical momentum is soft (below key moving averages with slightly negative MACD), valuation is difficult to support with a negative P/E and no dividend, and free cash flow remains modest and less consistent.

Positive Factors
Sustained Revenue GrowthCerus is demonstrating durable commercial expansion, with revenue rising materially over several years and growth accelerating in the latest period. Its recurring consumable model means broader blood-component adoption can support repeat purchasing and extend the company’s growth runway.
Negative Factors
GAAP Losses PersistCerus has not yet converted its improving revenue and adjusted EBITDA performance into consistent GAAP profitability. Continued operating and net losses can consume capital, limit financial flexibility, and leave earnings vulnerable if growth slows or commercialization costs remain elevated.

Cerus (CERS) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%CERS+33.22%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$400.88M
Dividend Yield
―
Average Volume (3M)
1.93M
Price to Earnings (P/E)
-51.2
Beta (1Y)
1.76
Revenue Growth
13.74%
EPS Growth
56.08%
Country
US
Employees
268
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Cerus Business Overview & Revenue Model

Company Description

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, the...

How the Company Makes Money

Cerus makes money primarily by selling its INTERCEPT Blood System products and related consumables used in routine blood-component processing. Revenue is generated from (1) sales of single-use INTERCEPT processing kits/sets and associated reagents th...

Cerus Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:-15.89%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Cerus reported double-digit product revenue growth, reaffirmed full-year guidance, continued ISC and platelet adoption, stronger cash generation, positive adjusted EBITDA for the tenth consecutive quarter, and positive Phase III REDeS top-line results. The principal challenges were geopolitical and foreign-exchange headwinds in EMEA, a year-over-year gross-margin decline, declining government contract revenue, pending regulatory questions, and CE Mark timing now expected in late 2027. The number and significance of the stated achievements outweighed the stated challenges.

Positive Updates

Product Revenue Growth and Guidance Reaffirmed
Third-quarter 2026 product revenue was $57.7 million, up 10% year-over-year. Product revenue for the first nine months increased 14% to $168.8 million. Cerus reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million, including ISC sales guidance of $23 million to $25 million.

Negative Updates

Geopolitical Headwinds in International Markets
Geopolitical conflicts in the Middle East and Russia, including the ongoing Russia-Ukraine conflict, created near-term headwinds. The company specifically cited an impact on Russian orders and said it was navigating acute issues affecting international business.

Company Guidance

Management reaffirmed full year 2026 product revenue guidance of $229 million to $231 million, including full year 2026 IFC sales of $23 million to $25 million, and expects essentially all ISC sales will be in kit form in 2027. Cerus’ operating priorities include delivering sustainable double digit annual growth; it expects INT200 placements in EMEA to continue in the fourth quarter and some relief in Q4 from foreign exchange headwinds, expects CE Mark clearance in late 27 followed by a limited market release targeting centers of excellence in Europe, and considers the first half of 27 a reasonable expectation for the full REDeS data analysis, while providing no 2027 product revenue guidance.

Cerus Financial Statement Overview

Summary

Fundamentals are improving but not yet fully proven. Revenue has expanded materially (2021 $130.9M to 2025 $206.1M; $226.6M TTM) and losses have narrowed substantially (net margin from -41.6% in 2021 to -7.6% in 2025 and -3.2% TTM), with TTM EBITDA slightly positive. Balance sheet risk has improved meaningfully with debt down to ~$40.1M in TTM and debt/equity ~0.53x, but profitability is still not consistently positive (TTM EBIT and net income remain negative) and free cash flow is only modestly positive in TTM ($0.5M) and down sharply versus 2025 ($8.5M).

Income Statement

54Neutral

Balance Sheet

62Positive

Cash Flow

46Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue226.57M206.13M180.27M156.37M162.05M130.86M
Gross Profit117.44M112.29M99.52M86.40M87.09M67.38M
EBITDA-5.16M-5.51M-10.02M-26.34M-33.52M-45.99M
Net Income-7.31M-15.63M-20.92M-37.49M-42.78M-54.37M
Balance Sheet
Total Assets204.73M221.86M200.92M197.75M218.09M237.50M
Cash, Cash Equivalents and Short-Term Investments57.11M82.88M80.45M65.85M102.15M129.36M
Total Debt74.96M96.95M98.10M96.00M87.24M87.59M
Total Liabilities128.37M156.89M144.02M144.30M149.53M151.88M
Stockholders Equity75.70M64.22M56.15M52.65M67.61M84.62M
Cash Flow
Free Cash Flow494.00K8.52M8.52M-47.77M-27.61M-34.83M
Operating Cash Flow3.50M11.36M11.36M-43.17M-25.61M-33.92M
Investing Cash Flow17.94M-8.13M-8.13M8.62M8.46M12.69M
Financing Cash Flow-21.10M4.96M4.96M10.67M4.19M34.29M

Cerus Technical Analysis

Technical Analysis SentimentNegative
Last Price1.99

Price Trends

50DMA2.36Negative
100DMA2.59Negative
200DMA2.43Negative

Market Momentum

MACD-0.10Positive
RSI38.64Neutral
STOCH16.94Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERS, the sentiment is Negative. The current price of 1.99 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.36, and below the 200-day MA of 2.43, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 38.64 is Neutral, neither overbought nor oversold. The STOCH value of 16.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CERS.

Cerus Risk Analysis

Cerus disclosed 39 risk factors in its most recent earnings report. Cerus reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our stock price is volatile and your investment may suffer a decline in value.Q4, 2023
2.The exclusive forum provisions in our amended and restated bylaws could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or any of our directors, officers or employees, or our stockholders, or the underwriters of any offering giving rise to such claim, which may discourage lawsuits with respect to such claims.Q4, 2023
3.Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.Q4, 2023

Cerus Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CERS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BIOBIO78Outperform$9.86B9.6014.07%―1.38%―
LIVNLIVN77Outperform$5.03B25.5115.35%―11.71%―
HAEHAE71Outperform$5.60B54.1612.07%―4.11%-34.22%
CERSCERS56Neutral$400.88M-51.16-10.54%―13.74%56.08%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CTSOCTSO47Neutral$15.35M-0.91-1339.98%―9.04%-43.07%
AEMDAEMD44Neutral$8.49M-0.50-141.22%――90.69%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%CERSBIOHAECTSOLIVNAEMDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CERS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CERSCerus Corporation1.990.4629.74%
BIOBio-Rad Laboratories366.3662.3020.49%
HAEHaemonetics122.9448.6265.42%
CTSOCytosorbents Corp4.87-8.25-62.89%
LIVNLivaNova PLC91.3237.6870.25%
AEMDAethlon5.29-14.96-73.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026